



## Vaccines against Bacterial Respiratory Infections

Guest Editors:

**Prof. Dr. Paul Langford**

**Dr. Vanessa S. Terra**

**Dr. Fadil Bidmos**

**Dr. Alice Halliday**

Deadline for manuscript  
submissions:  
**closed (31 October 2022)**

### Message from the Guest Editors

Dear Colleagues,

While accruing data is showing a reduction in the incidence of bacterial respiratory infections during the pandemic owing to public health measures introduced to tackle COVID-19, these diseases remain a huge threat, and a resurgence can be expected as the pandemic subsides. Research into the development of vaccines—which have proven to be indispensable in the fight against these infections—must continue, but now with the significant incorporation of new strategies and technologies, some of which were instrumental in the rapid development of the COVID-19 vaccines. This Special Issue of *Vaccines* will highlight specific groundbreaking research covering all stages of the bacterial vaccine development process, from antigen discovery through assessments of immune responses in experimental human challenge models to the monitoring of impact and non-specific events. In this Issue, focus will also be preferentially given to those bacterial pathogens that cause human disease.

Prof. Dr. Paul Langford

Dr. Vanessa S. Terra

Dr. Fadil Bidmos

Dr. Alice Halliday

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)